Medtronic says it launched a feasibility trial of its Valiant Mona LSA branch stent graft for treating aortic aneurysms affecting the left subclavian artery.
Medtronic (NYSE:MDT) said today that it launched a new feasibility study of its Valiant Mona LSA stent graft in treating aortic aneurysms affecting the left subclavian artery.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1zGR3v0
Cap comentari:
Publica un comentari a l'entrada